Jason Cohen

About the Author Jason Cohen

Jason is a Smarter Analyst editor and writer, who specializes in biotech and cannabis-based pharmaceutical companies.

Deciphera (DCPH) Stock at $62 a Share? Deutsche Bank Thinks It’s Possible

Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Deciphera Pharmaceuticals …

Is the Worst Over for Zogenix (ZGNX) Stock?

Zogenix (ZGNX) is one of the pharma’s biggest losers today. The reason?

Analyst Sings the Praises of Amarin (AMRN) Stock Following ADA Endorsement

With primary care clinicians playing an ever-increasing role in the management of diabetes, staying on top of new developments in the American Diabetes …

This Cannabis Stock Just Got a Huge Vote of Confidence

In one of the largest investments to date by a single investor in a publicly traded cannabis company, MedMen (MMNFF) announced this morning that …

This Analyst Takes Biogen (BIIB) Alzheimer’s Failure Personally

It’s a short and dramatic plunge for Biogen (BIIB) stock. Today, the biotech giant’s shares lost 29% of their value and reached levels …

Cannabis Strategies Acquisition (CBAQF) Stock at $26? Northland Thinks It’s Possible

There’s little doubt that the burgeoning pot industry offers plenty of opportunity for investors. According to a report by BDS Analytics, global consumer cannabis …

Spark Therapeutics (ONCE): Did You Feel the Ground Shake, Too?

It’s a very rewarding trading day for investors in Spark Therapeutics (ONCE) with shares skyrocketing 120%, making the stock Wall Street’s bull of …

Teva Stock Slips on Back of Weak 2019 Outlook; Analysts Weigh In

You know there was some bad news with a company’s quarterly update when the stock tanks after the results are announced. That’s what …

Don’t Say Bye Bye to Intercept (ICPT) Stock, Say Buy Buy

With Intercept (ICPT) preparing to release Phase 3 results from its REGENERATE study in Non-Alcoholic Steatohepatitis (NASH) patients, Gilead (GILD) announced yesterday that its top late-stage NASH drug …

MacroGenics (MGNX) Stock Fires on All Cylinders; Analysts Weigh In

It’s a very rewarding trading day for investors in MacroGenics (MGNX) with shares up over 120%, making the stock Wall Street’s bull of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts